Lupus erythematosus
☆ ໃນປີ 2022 Stiftung Warentest ຜົນໄດ້ຮັບຈາກເຢຍລະມັນ, ຄວາມພໍໃຈຂອງຜູ້ບໍລິໂພກກັບ ModelDerm ແມ່ນຕໍ່າກວ່າການປຶກສາຫາລືທາງດ້ານການປິ່ນປົວທາງໂທລະສັບເລັກນ້ອຍເທົ່ານັ້ນ.
ປາກົດເປັນ erythema ສີມ່ວງເລັກນ້ອຍ.
ຜື່ນຜີວຜີວທີ່ມັກຈະປາກົດຢູ່ໜ້າ.
References
ການກໍານົດແລະການຈັດປະເພດ cutaneous lupus erythematosus (CLE) ເຮັດໃຫ້ເກີດສິ່ງທ້າທາຍໃນການວິນິດໄສ, ແຍກແຍະມັນອອກຈາກ systemic lupus erythematosus ດ້ວຍການມີສ່ວນຮ່ວມຂອງຜິວຫນັງ. ການສຶກສາທີ່ຜ່ານມາໃຫ້ຄວາມສະຫວ່າງກ່ຽວກັບປັດໃຈພັນທຸກໍາ, ສິ່ງແວດລ້ອມ, ແລະພູມຕ້ານທານທີ່ຕິດພັນກັບ CLE. ການຍັບຍັ້ງຢາເສບຕິດໂດຍສະເພາະໄດ້ປະກົດອອກເປັນຫນຶ່ງໃນຜົນກະທົບຕໍ່ CLE ທີ່ສໍາຄັນທີ່ສຸດ. ການປິ່ນປົວກ່ຽວຂ້ອງກັບການປິ່ນປົວແບບກະເພາະແລະລະບົບ, ລວມທັງຊີວະວິທະຍາທີ່ໂດດເດັ່ນ (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , ໂດຍສະແດງໃຫ້ເຫັນປະສິດທິພາບໃນການທົດລອງທາງດ້ານການຊ່ວຍ.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) ກວມເອົາບັນຫາຜິວຫນັງຕ່າງໆ, ບາງອັນອາດຈະເຊື່ອມຕໍ່ກັບບັນຫາສຸຂະພາບຢ່າງກວ້າງຂວາງ. ມັນຖືກຈັດປະເພດເປັນປະເພດຕ່າງໆເຊັ່ນ: acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE ປະກອບດ້ວຍ discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus ແມ່ນກຸ່ມຂອງພະຍາດ autoimmune ທີ່ສາມາດສົ່ງຜົນກະທົບຕໍ່ພາກສ່ວນຕ່າງໆຂອງຮ່າງກາຍ. ບາງປະເພດ, ເຊັ່ນ systemic lupus erythematosus (SLE) , ຜົນກະທົບຕໍ່ອະໄວຍະວະຫຼາຍຊະນິດ, ໃນຂະນະທີ່ບາງຊະນິດ, ເຊັ່ນ cutaneous lupus erythematosus (CLE) , ສ່ວນໃຫຍ່ແມ່ນຜົນກະທົບຕໍ່ຜິວຫນັງ. ພວກເຮົາຈັດປະເພດ CLE ປະເພດຕ່າງໆໂດຍອີງໃສ່ການປະສົມຂອງອາການທາງດ້ານຄລີນິກ, ການກວດເນື້ອເຍື່ອ, ແລະການກວດເລືອດ, ແຕ່ມີຄວາມແຕກຕ່າງກັນຫຼາຍລະຫວ່າງບຸກຄົນ. ບັນຫາຜິວຫນັງມັກຈະເກີດຂື້ນຍ້ອນປັດໃຈເຊັ່ນການຖືກແສງແດດ, ການສູບຢາ, ຫຼືຢາບາງຊະນິດ.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
ສາເຫດຂອງ lupus erythematosus ແມ່ນບໍ່ຊັດເຈນ. ໃນບັນດາຄູ່ແຝດທີ່ຄ້າຍຄືກັນ, ຖ້າຫາກວ່າຜູ້ຫນຶ່ງໄດ້ຮັບຜົນກະທົບມີໂອກາດ 24% ອີກຫນຶ່ງຈະເປັນເຊັ່ນດຽວກັນ. ຮໍໂມນເພດຍິງ, ແສງແດດ, ການສູບຢາ, ການຂາດວິຕາມິນ D, ແລະການຕິດເຊື້ອບາງຢ່າງແມ່ນຍັງເຊື່ອວ່າຈະເພີ່ມຄວາມສ່ຽງ.
ການປິ່ນປົວອາດຈະປະກອບມີ NSAIDs, corticosteroids, immunosuppressants, hydroxychloroquine, ແລະ methotrexate. ເຖິງແມ່ນວ່າຢາ corticosteroids ມີປະສິດຕິຜົນ, ການນໍາໃຊ້ໃນໄລຍະຍາວເຮັດໃຫ້ຜົນຂ້າງຄຽງ.